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Abstract
Background: Early rapid fluid resuscitation (boluses) in African children with severe febrile illnesses increases the
48-hour mortality by 3.3% compared with controls (no bolus). We explored the effect of boluses on 48-hour all-
cause mortality by clinical presentation at enrolment, hemodynamic changes over the first hour, and on different
modes of death, according to terminal clinical events. We hypothesize that boluses may cause excess deaths from
neurological or respiratory events relating to fluid overload.
Methods: Pre-defined presentation syndromes (PS; severe acidosis or severe shock, respiratory, neurological) and
predominant terminal clinical events (cardiovascular collapse, respiratory, neurological) were described by
randomized arm (bolus versus control) in 3,141 severely ill febrile children with shock enrolled in the Fluid
Expansion as Supportive Therapy (FEAST) trial. Landmark analyses were used to compare early mortality in
treatment groups, conditional on changes in shock and hypoxia parameters. Competing risks methods were used
to estimate cumulative incidence curves and sub-hazard ratios to compare treatment groups in terms of terminal
clinical events.
Results: Of 2,396 out of 3,141 (76%) classifiable participants, 1,647 (69%) had a severe metabolic acidosis or severe
shock PS, 625 (26%) had a respiratory PS and 976 (41%) had a neurological PS, either alone or in combination. Mortality
was greatest among children fulfilling criteria for all three PS (28% bolus, 21% control) and lowest for lone respiratory
(2% bolus, 5% control) or neurological (3% bolus, 0% control) presentations. Excess mortality in bolus arms versus
control was apparent for all three PS, including all their component features. By one hour, shock had resolved
(responders) more frequently in bolus versus control groups (43% versus 32%, P <0.001), but excess mortality with
boluses was evident in responders (relative risk 1.98, 95% confidence interval 0.94 to 4.17, P = 0.06) and ‘non-
responders’ (relative risk 1.67, 95% confidence interval 1.23 to 2.28, P = 0.001), with no evidence of heterogeneity (P =
0.68). The major difference between bolus and control arms was the higher proportion of cardiogenic or shock terminal
clinical events in bolus arms (n = 123; 4.6% versus 2.6%, P = 0.008) rather than respiratory (n = 61; 2.2% versus 1.3%, P =
0.09) or neurological (n = 63, 2.1% versus 1.8%, P = 0.6) terminal clinical events.
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Conclusions: Excess mortality from boluses occurred in all subgroups of children. Contrary to expectation,
cardiovascular collapse rather than fluid overload appeared to contribute most to excess deaths with rapid fluid
resuscitation. These results should prompt a re-evaluation of evidence on fluid resuscitation for shock and a re-
appraisal of the rate, composition and volume of resuscitation fluids.
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Background
In the Fluid Expansion as Supportive Therapy (FEAST)
trial, African children with shock randomized to early
rapid fluid resuscitation (20 to 40 ml/kg boluses) with nor-
mal saline or 5% human albumin had a 3.3% increased
absolute risk of death by 48 hours compared with no-
bolus controls [1]. Following publication, commentary
papers, letters and discussion groups have speculated on
reasons for this surprising result [2-7], given that bolus
resuscitation is the gold standard for shock-management
in well-resourced countries (albeit based on weak levels of
evidence) [8].
FEAST was a pragmatic trial conducted in African hos-
pitals without ventilation facilities. It included children
with shock caused by a heterogeneous group of conditions
including sepsis [9] and malaria [10] but excluded those
with gastroenteritis and severe malnutrition [11]. Consis-
tency of adverse outcome was shown over all sites and in
all possible subgroups, with no benefit of boluses observed
for any working diagnosis [1], for any definition of shock
[7,12-14], or presence or absence of anemia or under-
nutrition. As reasons for harm caused by boluses remained
unclear, we undertook further analyses to explore possible
mechanisms and modes of death in children randomized
to bolus resuscitation versus control. We hypothesized
that boluses may cause excess deaths from neurological or
respiratory events, particularly those relating to fluid over-
load. We explored the effect of boluses on 48-hour mor-
tality according to signs and symptoms at enrolment
(presentation syndrome, PS); predominant clinical syn-
drome in each patient prior to death (terminal clinical
event, TCE); and changes in vital signs, measured prospec-
tively at pre-specified times.
Methods
Trial design and population
The methods and the outcome of the trial have been
reported in detail [1]. In brief, children, aged 60 days to
12 years, with severe febrile illness (classed as impaired
consciousness (prostration or coma) and/or respiratory dis-
tress (increased work of breathing) plus clinical evidence of
impaired perfusion (one of capillary refill time >2 seconds,
lower limb temperature gradient, weak radial pulse volume
or severe tachycardia) at six centers in Kenya, Tanzania
and Uganda were enrolled into two strata according to sys-
tolic blood pressure [1]. Stratum A included 3,141 children
without severe hypotension who were randomized to
immediate bolus of 20 ml/kg (increased to 40 ml/kg after
protocol amendment [1]) of 5% albumin (albumin-bolus:
1,050 children) or 0.9% saline (saline-bolus: 1,047 children),
or no-bolus (control, maintenance fluids 4 ml/kg/hour:
1,044 children). The saline-bolus and albumin-bolus arms,
but not the control arm, received an additional 20 ml/kg
bolus at one hour if impaired perfusion persisted. In all
three arms, further 40 ml/kg boluses of study fluid (saline
for the control arm) were only prescribed beyond one hour
if severe hypotension developed (see definition below).
Stratum B included 29 children with FEAST entry criteria
plus severe hypotension (defined as systolic blood pressure
<50 mmHg if <12 months; <60 mmHg if 1 to 5 years; <70
mmHg if > 5 years) who were randomized to albumin or
saline boluses of 40 to 60 ml/kg only. The primary end-
point was 48-hour mortality. Children with severe malnu-
trition, gastroenteritis, trauma, surgery or burns were
excluded.
Baseline and follow-up data collection
Trial clinicians completed a structured clinical case
report form at admission. A venous blood sample was
taken for immediate biochemical analyses with a hand-
held blood analyzer (iSTAT, Abbott Laboratories,
Abbott Park, IL, USA), hemoglobin was measured with
HemOcue (Ängelholm, Sweden), glucose and lactate
were measured with an On-Call glucometer and a Lac-
tate Pro meter respectively and HIV antibody testing.
Blood smears for malaria parasites were prepared for
immediate reading and subsequent quality control. Stan-
dardized clinical reviews were conducted at 1, 4, 8, 24
and 48 hours including vital signs and hemodynamic
monitoring. A working clinical diagnosis was recorded
at 48 hours as well as history of prior neurodevelopmen-
tal progress and any pre-admission neurological deficits.
Children were managed on general pediatric wards;
mechanical ventilation (other than short-term ‘bag-and-
mask’ support) was not available. Basic infrastructural
support for emergency care as well as oxygen saturation
Maitland et al. BMC Medicine 2013, 11:68
http://www.biomedcentral.com/1741-7015/11/68
Page 2 of 15
and automatic blood pressure monitors were provided for
each site. All trial patients received intravenous antibiotics,
antimalarial drugs (for those with falciparum malaria) and
intravenous maintenance fluids (2.5 to 4 ml/kg/hour as
per national guidelines) until the child was able to retain
oral fluids. Antipyretics, anticonvulsants and treatment for
hypoglycemia (blood sugar <2.5 mmol/l) were adminis-
tered according to nationally agreed protocols. Children
with a hemoglobin level <5 g/dl were transfused with
20 ml/kg of whole blood over 4 hours.
Assignment of presentation syndrome and terminal
clinical event
Prior to and throughout the trial, clinical staff received
onsite training in triage and emergency life support
management to optimize case recognition, implement
supportive management and ensure protocol adherence.
Throughout the hospital admission, severe adverse
events were reported immediately and clinical features
of pulmonary edema and raised intracranial pressure,
and evidence of hypovolemia and allergic events were
actively solicited. An independent clinician removed all
references to randomized arm or fluid management
prior to review by the Endpoint Review Committee
(ERC), which included an independent chair (JE), five
independent pediatricians (experienced in high depen-
dency care and/or working in Africa), and center princi-
pal investigators. The ERC had access to ‘blinded’
clinical narratives, bedside vital observations (below),
iSTAT results (baseline, 24 hours), microbiology,
malaria and HIV status, and concomitant treatments.
They adjudicated (blind to randomized arm) on whether
fatal and non-fatal events could be related to bolus
interventions and the main causes of death [1]. In addi-
tion, the ERC chairperson and another non-center ERC
member reviewed all deaths occurring within 48 hours;
using pre-specified criteria, they stratified all children by
presentation syndrome (PS) and classified the predomi-
nant clinical mode of death (TCE).
Presentation syndromes definitions
Severe shock or acidosis presentation was any one of
blood lactate >5 mmol/l [8], base excess >-8 mmol/l [10];
World Health Organization shock definition (all of cold
hands or feet; capillary refill time >3 seconds; weak and
fast pulse) [14] or moderate hypotension (systolic blood
pressure (SBP) 50 to 75 mmHg in children aged <12
months, 60 to 75 mmHg in children aged 1 to 5 years,
and 70 to 85 mmHg in children aged >5 years).
Respiratory presentation
hypoxia (oxygen saturation <92% measured by pulse oxi-
metry) [15] plus one of history of cough, chest indrawing
or crepitations [16].
Neurological presentation
coma or seizures at or immediately preceding hospital
admission [16].
Terminal clinical event syndrome definitions
Cardiogenic/cardiovascular collapse
signs of shock at the point of demise - severe tachycardia
or bradycardia plus one of prolonged capillary refill time
>2 seconds, cold peripheries or low SBP. If hypoxia was
also present then this mode of TCE was a consensus view
among ERC members, that circulatory failure was deemed
to be the primary problem.
Respiratory
Ongoing or development of hypoxia (PaO2 <90%) with
chest signs (crepitations or indrawing). Primary cause of
death assigned as pneumonia and/or involving possible
pulmonary edema.
Neurological
Possible raised intracranial pressure (high SBP or relative
bradycardia) or, in children with severely reduced con-
scious level (Blantyre Coma Score ≤2 [17]), focal neurolo-
gical signs, abnormal pupil response to light or posturing
at the point of demise.
Children whose deaths were unwitnessed were assigned
‘unknown’ TCE.
Analysis
The analysis focused on children in stratum A, in which
86% of deaths occurred within 48 hours. Stratum B (mor-
tality 62% (18 out of 29)) was not included because all
children received boluses [1]. Albumin- and saline-bolus
arms were combined, as mortality was very similar in
both. All comparisons between combined bolus and con-
trol arms were performed according to intention-to-treat,
and all statistical tests were two-sided.
PS prevalence was described by randomized arm and
48-hour mortality was compared by randomized arm
within each PS. Forest plots were constructed to show
comparisons between arms for 48-hour mortality accord-
ing to PS and all individual features of each PS. Hazard
ratios for the comparison between bolus and no-bolus
arms were estimated for different levels of oxygen satura-
tion and hemoglobin from Cox proportional hazard
models, with a single indicator for treatment group, the
level of the parameter and an interaction between treat-
ment group and parameter. Competing risks methods
were used to estimate cumulative incidence curves and
sub-hazard ratios to compare the two treatment groups
in terms of TCEs [18].
Oxygen saturation, axillary temperature, heart rate,
respiratory rate, SBP, glucose values and a composite
measure of shock or impaired perfusion (defined as any
of the following: capillary refill time >2 seconds, lower
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limb temperature gradient, weak radial pulse volume or
severe tachycardia (<12 months, >180 bpm; 1 to 5 years,
>160 bpm; >5 years, >140 bpm)) were summarized for
survivors over time (at baseline, 1, 4, 8, 24 and 48 hours)
with box and whisker plots and bar charts. Treatment
groups were compared in terms of mortality after one
hour, conditional on changes in shock and hypoxia para-
meters 1-hour post-randomization. Our analyses focused
only on early changes where the number of deaths was
similar across randomized arms; thereafter, because of
excess deaths in bolus arms, results would be subject to
survivorship bias.
Ethics statement
Ethics Committees of Imperial College London, Maker-
ere University Uganda, Medical Research Institute, Kenya
and National Medical Research Institute, Tanzania
approved the protocol.
Results
In FEAST stratum A, 3,141 children were randomized
between 13 January 2009 and 13 January 2011 (1,050 albu-
min-bolus, 1,047 saline-bolus, 1,044 control) (Figure 1).
Baseline characteristics were similar across arms and med-
ian age was 24 months (interquartile range 13 to 38
months). Overall, 2,398 (76%) had impaired consciousness
(including 457 (15%) with unarousable coma), 1,172 (37%)
had convulsions and 2,585 (83%) had respiratory distress.
Plasmodium falciparum malaria parasitemia was present
in 1,793 out of 3,123 (57%); severe anemia (hemoglobin
<5 g/dl) in 987 out of 3,054 (32%); 1,070 out of 2,079
(52%) had a base deficit > 8mmol/L; 1,159 out of 2,981
(39%) had a lactate level >5mmol/l; 126 out of 1,070 (12%)
had bacteremia (positive blood culture); and 10 out of 292
(3%) had meningitis (positive cerebrospinal fluid culture).
Presentation syndromes
Of the 3,141 children in stratum A, 2,396 (76%) could be
classified into a single PS or a combination; 633 (20%)
cases had missing base excess (589) or lactate (32) or
blood pressure (12), thus precluding classification to shock
or acidosis PS, but half of these had additional respiratory
and/or neurological presentations (Figure 2a,b; Table S1 in
Additional file 1). In 112 children (4%), information was
missing on two or more PS. Of the 2,396 children with full
information, 1,647 (69%) had severe metabolic acidosis or
severe shock, 625 (26%) had respiratory presentations and
976 (41%) had neurological presentations, alone or in
combination. The distribution of PS was balanced across
randomized arms (Table S1 in Additional file 1).
Mortality by presenting syndrome
Mortality was greatest among children fulfilling criteria for
all three PS (28% bolus, 21% control) and combined shock
or acidosis and respiratory presentations (19% bolus, 18%
control). The greatest differences in mortality between
bolus and control groups was among those with all three
PS (n = 205) and those with severe shock or acidosis PS
alone (n = 698; 10% bolus, 3% control). These two groups
represented 37% (898 out of 2,396) of classifiable cases.
Mortality was lowest for respiratory presentation alone
(2% bolus, 5% control) or neurological presentation alone
(3% bolus, 0% control) (Figure 2a). A small number, 363
out of 2,396 (15%), had only FEAST entry criteria; three
children died in this group (2% bolus; 0% control).
We found no evidence that the excess 48-hour mortality
in bolus arms versus the control arm differed by PS
(Figure 3) or by individual clinical components of each PS
(Figures 4, 5 and 6) (all P-values for heterogeneity ≥0.2).
The exception was hypoxia (oxygen saturations <92%),
present in 856 children (27%) at admission. As expected,
hypoxia was a strong predictor of higher subsequent mor-
tality, but there was statistically significant evidence that
the excess mortality with boluses was greater in the sub-
group without hypoxia at presentation (bolus versus con-
trol, relative risk (RR) 1.94, 95% confidence interval (CI)
1.31 to 2.89) than in the subgroup with hypoxia (RR 1.13,
95%CI 0.79 to 1.16; heterogeneity P = 0.04, Figure 4). This
is also demonstrated with oxygen saturation as a continu-
ous variable in Figure S2 in Additional file 1. Conversely,
and as reported previously, the degree of anemia at admis-
sion had no significant impact on the effect of boluses on
overall mortality [1,7], excess harm being evident in the
bolus arms versus control across the whole range of base-
line hemoglobin values (Figure S3 in Additional file 1).
Terminal clinical events
In stratum A, 345 out of 3,141 children (11%) died; of
these, 297 deaths (86%) occurred within 48 hours. Primary
working diagnoses, recorded by clinicians and reported
previously [1], included malaria 142 (48%), pneumonia or
respiratory etiology 41 (14%); septicemia 27 (9%), anemia
27 (9%), meningitis 15 (5%), encephalitis 7 (2%), other
diagnosis 12 (4%) and insufficient information 26 (9%).
The ERC adjudicated 265 single and 32 (11%) combined
TCEs: 247 (83%) were judged to have a primary cardio-
genic, respiratory or neurological TCE [1].
A cardiovascular or shock TCE was the most frequent
overall (n = 123 (41%)); neurological and respiratory TCEs
occurred in 63 children (21%) and 61 children (20.5%)
respectively (Figure 7); in 18 children the TCE was
unknown. As expected, TCE generally aligned with PS
(Table S2 in Additional file 1).
Terminal clinical event-specific mortality by randomization
arm
The major difference between bolus and control arms was
the higher proportion of deaths adjudicated as having a
cardiogenic or shock TCE in bolus arms, 96 (4.6%) com-
pared with 27 (2.6%) in the control arm (sub-hazard ratio
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1.79, 95%CI 1.17 to 2.74, P = 0.008, Figure 7). This differ-
ence was even greater when 39 modes of death in 39
children who died in the first hour (when bolus adminis-
tration was incomplete) were excluded (79 (3.8%) com-
pared with 19 (1.8%) respectively of modes of death were
cardiogenic (sub-hazard ratio 2.09, 95%CI 1.27 to 3.45,
P = 0.004)). Of note, and as expected, 25 out of 39 early
deaths (64%) were cardiogenic.
We found no evidence for increased risk of neurological
events (putative ‘cerebral edema’) with boluses: there were
Figure 1 Patient flow. 1Inclusion criteria: Children aged >60 days and <12 years with severe febrile illness including impaired consciousness
(prostration or coma) and/or respiratory distress (increased work of breathing) were screened for clinical evidence of impaired perfusion (shock) to be
eligible for the trial. Impaired perfusion was defined as any one of the following: CRT 3 or more secs, lower limb temperature gradient, a weak radial
pulse volume or severe tachycardia: (<12 months: >180 beats per minute (bpm); 12 months to 5 years: >160bpm; >5 years: >140 bpm). 2Exclusion
criteria: Evidence of severe acute malnutrition (visible severe wasting or kwashiorkor); gastroenteritis; chronic renal failure, pulmonary edema or other
conditions in which volume expansion is contraindicated; non-infectious causes of severe illness (68); if they already received an isotonic volume
resuscitation. 3Other reasons for exclusion: child unable to return for follow-up (111), enrolled in a different study (65), no trial packs/fluid or blood (47),
previously enrolled to FEAST (17), died (11), other (181), missing reason (26). 4Severe hypotension defined as systolic blood pressure <50mmHg if
<12m; <60mmHg if 1-5years; <70mmHg if >5years- eligible children with severe hypotension were enrolled into FEAST B (see text) 5Child was not
febrile (had no fever or history of fever). 6One child had severe hypotension and one child did not have impaired perfusion.
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Figure 2 Mortality at 48 hours by presentation syndrome. (a) Complete information; n = 2,396. (b) Incomplete information; n = 745.
48-hour mortality by presentation syndrome and in bolus (albumin and saline) and control (no bolus) arms for those for which severe shock or
acidosis (n = 633), or respiratory syndrome (n = 105) or neurological syndrome (n = 8) could not be ascertained. Areas are proportional to the
size of subgroups. B: bolus arm; C: control arm.
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44 neurological TCEs in bolus arms (2.1%) versus 19
(1.8%) in the control arm (P = 0.6). Respiratory TCEs
(putative ‘pulmonary edema’) were marginally more com-
mon in bolus arms: 47 (2.2%) versus 14 (1.3%); P = 0.09
(Figure 7). No significant differences were found between
albumin or saline boluses for any TCE.
The cumulative incidence of death by TCE for all chil-
dren by bolus versus control arms is shown in Figure 7,
where, for clarity, single and combined TCEs are redistrib-
uted so that cardiogenic and neurological TCEs are
included with cardiogenic alone, and neurological and
respiratory (largely terminal lung aspiration in a comatose
child) are included with neurological alone. Cumulative
incidence for individual and combined TCE categories is
shown in Figure S4a,b in Additional file 1.
Terminal clinical events according to bolus volume, malaria
status and hemoglobin
The effect of a bolus had similar patterns on TCEs in
children receiving 20 ml/kg and 40 ml/kg (that is, before
and after the protocol amendment), among children with
and without malaria, and in those with and without
severe anemia. In all groups, cardiogenic TCEs accounted
for the greatest excess in mortality in the bolus versus
control groups, with no evidence of heterogeneity (all
P-values > 0.1) (Tables S3a,b,c in Additional file 1).
Changes in hemodynamics, vital status and laboratory
parameters over time
Box and whisker plots of individual bedside vital status
observations, including heart rate, respiratory rate oxygen
saturation, consciousness level and hypoglycemia (blood
glucose < 3 mmol/L) showed improvement over time, with
few differences between bolus and control arms (Figure S1
in Additional file 1). The exception was the composite mea-
sure of impaired perfusion (first box and whiskers plot in
panel in Figure S1 in Additional file 1), which by one hour
had resolved more frequently in the bolus than control
arms; 43% of bolus-recipients had no sign of impaired perfu-
sion compared with only 32% in the control arm (P ≤ 0.001).
Figure 3 Mortality risk at 48 hours for bolus compared to no bolus by presentation syndromes at baseline. Forest plots comparing
effect of bolus versus no bolus for each baseline presentation syndrome (respiratory, neurological or severe shock or acidosis); children could be
assigned to more than one syndrome.
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Hemodynamic responses and changes in oxygen status at
one hour
The mortality at 48 hours was significantly higher among
1,881 children with persistent impaired perfusion (see ana-
lysis section for definition) at one hour (non-responders)
compared with 1,198 responders (shock-resolution) (10%
versus 4%, P <0.001, Table S4a in Additional file 1). How-
ever, despite greater improvements in perfusion in the
bolus arm at one hour, excess mortality in bolus versus
control arms was evident in non-responders (RR 1.67, 95%
CI 1.23 to 2.28, P = 0.001) as well as responders (RR 1.98,
95%CI 0.94 to 4.17, P = 0.06), with no evidence that these
were different (heterogeneity P = 0.68, Table S4a in Addi-
tional file 1).
Children with baseline hypoxia who remained hypoxic
at one hour had increased risk of subsequent mortality
Figure 4 Mortality risk at 48 hours for bolus compared to no bolus by individual respiratory symptoms/signs at baseline.
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compared with those whose hypoxia resolved (18% ver-
sus 7%, P <0.001, Table S4b in Additional file 1). There
was no evidence to indicate that boluses were associated
with increased mortality in the children with persistent
hypoxia compared with control children (RR 0.71, 95%
CI 0.43 to 1.18). Among children whose hypoxia had
resolved by one hour, the RR of mortality for bolus ver-
sus control was 1.45 (95%CI 0.73 to 2.85, heterogeneity
P = 0.1, Table S4b in Additional file 1).
A total of 175 out of 2144 children without hypoxia at
baseline (8%) developed hypoxia by one hour and, as
expected, had higher mortality compared with those who
did not develop hypoxia (15% versus 5%, bottom panel of
Table S4b in Additional file 1). Slightly more children in
the bolus arms than in the control arm (129 (9%) versus 46
(7%)) developed hypoxia by one hour. However, excess risk
of death in the bolus versus control arms was observed
among both children who developed hypoxia (RR 1.96,
95%CI 0.71 to 5.39) and those who remained non-hypoxic
(RR 2.64, 95%CI 1.53 to 4.54). Thus, overall, there was no
evidence that development of de novo hypoxia by one hour
impacted on the excess mortality in fluid bolus versus con-
trol arms (P-value for heterogeneity = 0.63, Table S4b in
Additional file 1).
Discussion
In this paper, we have explored possible mechanisms for
the excess death rate among children randomized to
receive rapid boluses of 20 to 40 ml/kg of 5% albumin or
0.9% saline fluid resuscitation compared with no-bolus
controls. We found no evidence that excess 48-hour mor-
tality associated with boluses differed by type of PS, by
individual constituent components of each syndrome, or
by baseline hemoglobin level. Remarkably, in every sub-
group we examined, there was consistent evidence of
harm by boluses. Paradoxically, the syndromes where
Figure 5 Mortality risk at 48 hours for bolus compared to no bolus by individual neurological signs/symptoms at baseline.
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most concern has been expressed over trial inclusion
(respiratory or neurological alone and/or less severe shock
criteria) not only had lower mortality overall, but also
tended to have smaller differences between bolus and con-
trol, although care must be taken with interpretation of
smaller subgroups. The only exception was hypoxia, pre-
sent in a quarter of children at admission, which surpris-
ingly appeared to be associated with significantly less
harm from boluses. There appears to be no good rationale
for this finding, which could have occurred by chance.
Even though this trial was conducted in settings with
limited resources and no access to intensive care, the con-
duct of the trial complied to the highest standards of good
clinical practice including adherence to intervention strat-
egy and completeness of follow-up, 100% source docu-
ment monitoring and the robust and blinded methodology
Figure 6 Mortality risk 48 hours for bolus compared to no bolus by shock-related or systemic signs at baseline.
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for determining PS and TCE. An intention-to-treat analysis
with no need for imputation for missing data minimized
the likelihood of bias and underpinned the magnitude and
importance of the unexpected findings of the trial and
further analyses.
Noteworthy is that, consistent with global clinical
experience, we observed a superior resolution of impaired
perfusion by one hour in the bolus arms compared with
the control arm. However, importantly, this did not trans-
late into a superior outcome when compared with children
Figure 7 Cumulative incidence of mortality for bolus combined and no bolus arms by terminal clinical events for 297 children who
died within 48 hours.
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with continued impaired perfusion: in both cases, boluses
resulted in higher mortality. Mortality excess with boluses
among children with and without hypoxia at baseline
occurred to a similar extent irrespective of oxygen satura-
tion status at one hour. Although de novo development of
hypoxia at one hour was more common in the bolus arms,
it was not associated with a significant increase in 48-hour
mortality - suggesting that, if fluid boluses were causing
pulmonary edema (and hypoxia), this was not a unifying
mechanism for increased mortality from boluses. More-
over, there was little evidence that fluid overload was the
mechanism for excess deaths with boluses from our ana-
lyses of neurological or respiratory TCEs. Overall, cardio-
vascular collapse was the main TCE and contributed most
substantially to the excess mortality in the bolus arms
compared to control, peaking at 2 to 11 hours post-bolus.
Whilst it is possible that subtle effects of fluid overload on
the lungs or brain could have been missed, our findings do
not lend support to this hypothesis, particularly as the
ERC review process was blind to randomization and used
pre-specified TCE definitions.
A limitation of our trial was that we were unable to
undertake invasive or point-of-care continuous monitoring
to provide greater insight into TCEs, as in high-income
intensive care settings. However, the availability of patient-
centered variables from our bedside observations and
laboratory data from most children at baseline has enabled
further characterization of the trial participants into clini-
cally relevant presentations (PS) in the context of where
the trial was conducted. It has provided a more in-depth
understanding of the spectrum of clinical groupings of
children enrolled in the trial and the degree of adverse
outcome fluid boluses had in these groups. Our bedside
observations at pre-defined times following randomization,
as well as adjudication of cause of death by the ERC, blind
to randomized arm and using pre-specified criteria (TCE),
provide more speculative data but remain informative
because they are largely operator-independent. These
methodologies are central to the internal validity of our
analysis, which sought to minimize systematic bias.
Whereas initial improvement in circulatory status fol-
lowing bolus resuscitation is consistent with global clinical
experience [8,12,19], the observation of excess subsequent
cardiovascular collapse and excess mortality, even in the
early responders, was only made possible because of
exemplary adherence to randomized allocation, and in a
trial protocol in which further boluses were given to only
(very few) children developing severe hypotension [12].
The possibility that fluid resuscitation lead to hemodilu-
tion [20,21] in already anemic children, reducing oxygen
delivery to the myocardium [22] and leading to ischemia
and cardiac dysfunction, is largely ruled out by the lack of
heterogeneity in the TCEs by hemoglobin level, and by the
analysis showing excess harm with fluids across the whole
range of hemoglobin values. These findings challenge the
presumption that early and rapid reversal of shock by fluid
resuscitation translates into longer-term survival benefits
[8,23,24] in settings where intensive care facilities are not
available. They do raise a possibility that rapid fluid resus-
citation may cause adverse effects on vascular hemo-
dynamics and myocardial performance, driving the
requirement for inotropic and pressor support. Rapid
restoration of microcirculatory perfusion may come at the
expense of requiring other components of the sepsis bun-
dle, including inotropes and ventilation. This possibility
could be explored in future clinical and preclinical
research examining the natural history of shock in patients
managed by maintenance only (as in the control arm) and
with fluid boluses.
Adverse effects of hyperchloremia, at the doses given in
this trial, remain controversial [25-29]. Intriguingly, the
most deleterious effects of boluses were in those patients
with severe acidosis at baseline, the group with the least
a priori equipoise regarding the potential benefits of fluid
resuscitation - lending support to the notion of adverse
effects of the resuscitation fluids on acid-base equilibrium.
Alternatively, this may indicate lethal reperfusion injury
[30] or a surge of cytokines [31] in cases with advanced
shock. As previously suggested [1], shock may be an adap-
tive, time-dependent response sustaining children through
a prolonged period prior to hospital admission - only to
die within hours of reperfusion.
Whatever the explanation, these findings raise important
questions about the pathophysiological mechanisms of
shock and goal-directed management, questioning
whether the protocol-driven requirement for inotropes
and vasoactive drugs has been driven, in part, by aggres-
sive fluid challenge [12]. The 2008 Surviving Sepsis Cam-
paign Guidelines, informed by a modified Delphi process,
graded the pediatric recommendation (20 ml/kg boluses
over 5 to 10 minutes up to 60 ml/kg) as 2C, indicating a
weak recommendation with low quality of evidence. The
pediatric studies on which these recommendations were
based included only two retrospective, observational stu-
dies of initial resuscitation volume on the outcome of chil-
dren with putative sepsis from a single tertiary referral
center, involving 34 and 91 children respectively [19,24].
The inclusion criteria for both studies were children who
survived to intensive care unit admission, but were ino-
trope-dependent and had pulmonary arterial catheters in
situ. Higher initial fluid boluses and early shock reversal in
9 and 24 children in the two respective studies were asso-
ciated with improved global outcome. However, the study
design and the patient population had major limitations in
terms of survivorship bias and external validity to other
settings. Other sources of evidence that were referenced to
inform fluid resuscitation guidelines include dengue
shock. We suggest these are largely irrelevant to the
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management of sepsis, because shock as a complication
of dengue occurs 7 to 10 days after fever defervescence,
secondary to gross intravascular leakage leading to vomit-
ing, abdominal pain, increasingly tender hepatomegaly,
narrow pulse pressure and hemoconcentration [32]. The
American College of Critical Care Medicine guideline, and
similar guidelines, nevertheless have been adopted by
many countries worldwide where point-of-care testing and
intensive care facilities are available and are considered to
be best practice. These are now being recommended as
standards of care for resource-poor settings [33,34]; indi-
cating that the FEAST trial had limited generalizability
because the adverse effects of fluid boluses were largely
confined to children with malaria and/or anemia [33]. The
data presented in the original manuscript [1], subsequence
correspondence [7] and this detailed sub-analysis definitely
counter this interpretation. A recent systematic review
assessing the evidence base for fluid resuscitation in the
treatment of children with shock due to sepsis or severe
infection found only 13 pediatric trials. Whilst the majority
of all randomized evidence to date comes from the FEAST
trial, they recommended that implementation of simple
algorithms for children managed at hospitals with limited
resources to ensure identification of children who maybe
potentially be harmed by fluid boluses [35]. The findings
we report here raise questions over the rates, volumes and
types of solutions recommended in pediatric resuscitation
protocols, most of which remain untested in clinical trials.
Conclusions
The results of the FEAST trial together with findings from
these additional analyses suggest that rapid administration
of fluid boluses increase the risk of subsequent cardiovas-
cular collapse in children with shock, rather than increas-
ing the risk of fatal fluid overload. The results suggest the
need for further research to better understand the patho-
physiology of shock and its treatment, and the mechan-
isms whereby rapid fluid resuscitation increased mortality
in African children.
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